Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June

argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026

argenx announced that Phase 3 ALKIVIA study results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis will be presented as a late-breaking oral presentation at ACR Convergence 2026. The study met its primary endpoint, showing a 15.4-point greater improvement in Total Improvement Score versus placebo at Week 52 in the combined IMNM and DM population, with improvements observed as early as Week 4 and sustained through 52 weeks. The drug was well-tolerated with a consistent safety profile.

argenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026

Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DM Patient

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1356

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1355 to $1356.

Oppenheimer Maintains Outperform on argenx, Lowers Price Target to $1038

Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1100 to $1038.

Capricor Therapeutics shares are trading lower after the company announced extension data from its ongoing HOPE-3 OLE study of Deramiocel on upper limb in Duchenne muscular dystrophy, which included 12-month and 24-month observations.

What's Going On With Capricor Therapeutics Stock Monday?

Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of its Nov 22 FDA PDUFA date.